Reena
504 posts

Reena retweetledi

🚨NEW MAJOR GUIDELINE!🚨
Managing blood pressure in patients on dialysis
One of the first of its kind, this unique & comprehensive guideline makes key recommendations for BP targets, treatment & care strategies.
➡️Download now to discover more: ow.ly/pABq50ViWCB

English
Reena retweetledi

Point-of-care summary of core HFrEF GDMT safety across CKD stages/ ESKD from @ruey_hu @KidneyInCVD
#Nephpearls #Cardiorenal
👉 gdmt.org/Contest/


Riverside, IL 🇺🇸 English
Reena retweetledi

IgA Nephropathy (IgAN) ca. 2024 from @JASN_News #Nephpearls
📌 Pathogenesis (4 hit hypothesis)
📌 Complement Pathway
📌 Trials
👉🏼 pubmed.ncbi.nlm.nih.gov/37772889/




Maywood, IL 🇺🇸 English
Reena retweetledi

Early steroid withdrawal and kidney transplant outcomes in first-transplant and retransplant recipients
doi.org/10.1093/ndt/gf…

English
Reena retweetledi

Exciting to see this shared! Here's the full paper for anyone interested: frontiersin.org/journals/nephr…
Abdelhamid Hamdy@abdelhamed012
Lupus medications 💊 during pregnancy and lactation
English

Ten tips on immunosuppression in primary membranous nephropathy academic.oup.com/ckj/article/17…
English

Immune checkpoint inhibitor-associated nephritis - treatment standard academic.oup.com/ndt/article-ab…
English
Reena retweetledi

New: Either ACEi or ARB therapy protect against kidney failure in those with advanced CKD. Neither therapy provided a death benefit for those with late-stage CKD: ecs.page.link/SWNAD

English
Reena retweetledi

Complement inhibitors ca. 2024 from @Kidney_Int @goKDIGO #Nephpearls
👉 pubmed.ncbi.nlm.nih.gov/38844295/


Català
Reena retweetledi

💡ACTUALIZACIÓN @goKDIGO 2024 Clinical Practice Guideline for Antineutrophilic Cytoplasmic Antibody (ANCA)-associated Vasculitis:
🚀kdigo.org/wp-content/upl…
🚀kdigo.org/guidelines/ant…



Català
Reena retweetledi

Wow
Minimal change disease RIP
Roughly half (higher in kids?) = anti nephrin podocytopathy
Multicentre study validating @AstridWeins et al findings at #ERA24 in @NEJM
nejm.org/doi/full/10.10…

English
Reena retweetledi

Presented at #ERA24:
FLOW trial: In patients with type 2 diabetes and chronic kidney disease, weekly semaglutide significantly reduced risks of major kidney events, cardiovascular events, and death from any cause while slowing loss of kidney function. nej.md/44U3slP

English
Reena retweetledi

Lipid management in CKD from @goKDIGO
#NephJC #Nephpearls
#VisualGraphic by @VamsidharV17
👉kdigo.org/guidelines/ckd…

English
Reena retweetledi

Two recent reviews of #ANCA vasculitis with wonderful graphics, and for the first time I think, #PR3🔹 and #MPO🔸 phenotypes are considered in parallel but SEPARATELY! A new era with individualized treatment is coming for sure!
🔹doi.org/10.1016/s2665-…
🔸doi.org/10.1016/s2665-…



English
Reena retweetledi

✅ It is my IMMENSE PLEASURE to share with you our SEMINAR on systemic #Lupus just published in... The LANCET!!!!! Amazing work driven by @alberta_hoi 👍
LINK: authors.elsevier.com/a/1ixq7V-4XOrME

English

Systemic lupus erythematosus - ScienceDirect sciencedirect.com/science/articl…
Română
Reena retweetledi

Updated Review of Membranous Nephropathy ca. 2024 from @indianjnephrol @OrhanEfe_ @nikkonephro @AnandhUrmila @NWiegley @GlomCon #Nephpearls
👉🏼 indianjnephrol.org/an-updated-rev…




Maywood, IL 🇺🇸 English





